Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy

Blood

Volumn 103, Issue 4, 2004, Pages 1485-1494

  Du, Yong ^a   Honeychurch, Jamie ^a   Cragg, Mark S ^a   Bayne, Mike ^a   Glennie, Martin J ^a   Johnson, Peter W M ^a   Illidge, Tim M ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; IODINE 131; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG HALF LIFE; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SIGNAL TRANSDUCTION; SPLEEN; TUMOR CELL;

EID: 0842285646     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2037     Document Type: Article

References (45)

1. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today. 2000;21:403-410.
2. Illidge TM, Bayne MC. Antibody therapy of lymphoma. Expert Opin Pharmacother. 2001;2:953-961.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
4. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
5. White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood. 1996;87:3640-3649.
6. Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:3292s-3303s.
7. Illidge TM, Johnson PW. The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol. 2000;108:679-688.
8. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
9. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696-1711.
10. Press OW, Eary JF, Appelbaum FR, et al. Radio-labeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
11. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
12. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
13. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
14. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of Non-Hodgkin's Lymphomas. In: Hematology: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2001:221-240.
15. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
16. Illidge TM, Cragg MS, McBride HM, French RR, Glennie MJ. The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma. Blood. 1999;94:233-243.
17. Tutt AL, French RR, Illidge TM, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol. 1998;161:3176-3185.
18. Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature. 1978;272:624-626.
19. Cobb LM, Glennie MJ, McBride HM, Breckon G, Richardson TC. Characterisation of a new murine B cell lymphoma. Br J Cancer. 1986;54:807-818.
20. Illidge T, Honeychurch J, Howatt W, Ross F, Wilkins B, Cragg M. A new in vivo and in vitro B cell lymphoma model, pi-BCL1. Cancer Biother Radiopharm. 2000;15:571-580.
21. George AJ, McBride HM, Glennie MJ, Smith LJ, Stevenson FK. Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants. Hybridoma. 1991;10:219-227.
22. Krop I, de Fougerolles AR, Hardy RR, Allison M, Schlissel MS, Fearon DT. Self-renewal of B-1 lymphocytes is dependent on CD19. Eur J Immunol. 1996;26:238-242.
23. Torres RM, Law CL, Santos-Argumedo L, et al. Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule. J Immunol. 1992;149:2641-2649.
24. Elliott TJ, Glennie MJ, McBride HM, Stevenson GT. Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy. J Immunol. 1987;138:981-988.
25. Badger CC, Davis J, Nourigat C, et al. Biodistribution and closimetry following infusion of antibodies labeled with large amounts of 131I. Cancer Res. 1991;51:5921-5928.
26. Loevinger R. MIRD Primer for Absorbed Dose Calculations. New York, NY: The Society of Nuclear Medicine Inc; 1988.
27. Peto R. Editorial: guidelines on the analysis of tumour rates and death rates in experimental animals. Br J Cancer. 1974;29:101-105.
28. Cobbold SP, Martin G, Waldmann H. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol. 1990;20:2747-2755.
29. Vuist WM, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood. 1994;83:899-906.
30. Grafton G, Goodall M, Gregory CD, Gordon J. Mechanisms of antigen receptor-dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies. Cell Immunol. 1997;182:45-56.
31. Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med. 1995;182:1815-1823.
32. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989;49:4906-4912.
33. Vervoordeldonk SF, Merle PA, van Leeuwen EF, von dem Borne AE, Slaper-Cortenbach IC. Pre-linical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer. 1994;73:1006-1011.
34. DeNardo GL, Siantar CL, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm. 2002;17:107-118.
35. Sgouros G, Squeri S, Ballangrud AM, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
36. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65:1349-1363.
37. Dechant M, Bruenke J, Valerius T. HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol. 2003;30:465-475.
38. Longo DL, Duffey PL, Gribben JG, et al. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J. 2000;6:146-150.
39. Cragg MS, Zhang L, French RR, Glennie MJ. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells. Br J Cancer. 1999;79:850-857.
40. Donjerkovic D, Scott DW. Activation-induced cell death in B lymphocytes. Cell Res. 2000;10:179-192.
41. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2:945-956.
42. Chaouchi N, Vazquez A, Galanaud P, Leprince C, B cell antigen receptor-mediated apoptosis: importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol. 1995;154:3096-3104.
43. Marches R, Racila E, Tucker TF, et al. Tumour dormancy and cell signaling, III: role of hyper-crosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther Immunol. 1995;2:125-136.
44. Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154:4466-4475.
45. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood. 2003;102:1449-1457.